Ocumetics, Medicel modify lens delivery technology

Executive Summary

• Ocumetics Technology Corp. has announced an optimized lens delivery system developed in collaboration with Medicel AG, incorporating feedback from surgeons following first-in-human implantation procedures.
• The updated system is designed to improve loading efficiency, streamline implantation, and ensure compatibility with the Ocumetics lens, aiming to maximize surgeon acceptance.
• The company intends to utilize this optimized delivery system for its upcoming Group 2 surgeries, which are planned for early 2026.

Key Details

• Collaboration Partner: Medicel AG, a global leader in ophthalmic device delivery systems.
• Technology Update: Modified lens delivery technology based on surgeon input from first-in-human lens implantation procedures.
• Design Goals: Optimize loading efficiency, streamline implantation procedures, and assure compatibility with the unique mechanical properties of the Ocumetics lens.
• Expected Outcome: Smoother insertion and maximized surgeon acceptance as the company progresses toward expanded clinical studies.
• Clinical Timeline: The optimized system will be used for Group 2 surgeries planned for early 2026.
• Product Context: Ocumetics is developing an intraocular lens that fits within the natural lens compartment, designed to allow the eye's natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses.
• Development Phase: The company is currently in the first-in-human early feasibility study phase.

Notable Quotes

• "The surgeon who performed our first-in-human implantations has been instrumental in shaping further improvements in the design of our lens delivery system that will be invaluable as we work to optimize the final configuration of the Ocumetics lens." — Dean Burns, President and CEO, Ocumetics.
• "Medicel's willingness to innovate rapidly and refine their delivery platform for the Ocumetics lens based on surgeon feedback demonstrates the strength of our partnership and Medicel's commitment to supporting next-generation accommodating intraocular lens technologies." — Dean Burns, President and CEO, Ocumetics.